umifenovir has been researched along with Chronic Hepatitis C in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Armen, RS; Freidel, MR | 1 |
| Boriskin, YS; Pécheur, EI; Polyak, SJ | 1 |
2 other study(ies) available for umifenovir and Chronic Hepatitis C
| Article | Year |
|---|---|
Modeling the Structure-Activity Relationship of Arbidol Derivatives and Other SARS-CoV-2 Fusion Inhibitors Targeting the S2 Segment of the Spike Protein.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; COVID-19; Hepatitis C, Chronic; Humans; Indoles; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Structure-Activity Relationship; Virus Internalization | 2021 |
Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection.
Topics: Acute Disease; Antiviral Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Indoles; Interferon-beta; Membrane Fusion; Microbial Viability; Receptors, Retinoic Acid; RNA, Viral; Signal Transduction; Virus Replication | 2006 |